All In Biotech

Drug Trial Radar · NCT04709913

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

A Double-blind, Sponsor-Open, Placebo-controlled, Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of HU6 in High BMI Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 4, 2021

Primary completion

Apr 30, 2021

Study completion Jul 30, 2021

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 14-day multiple ascending dose trial in high BMI volunteers in up to 4 cohorts of 10 high BMI volunteers each consisting of 8 receiving HU6 and 2 receiving placebo. Upon review of the safety and PK data, it may be decided to expand the current cohort size and/or dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 4 cohorts based on safety and/or PK and/or PD data, or enlist an additional cohort at a higher dose if deemed safe.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • HU6Drug

    HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the dose relationship of PK Parameter CmaxTime frame: 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prism Clinical Research

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.